<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02946879</url>
  </required_header>
  <id_info>
    <org_study_id>MGT004</org_study_id>
    <secondary_id>2016-000898-20</secondary_id>
    <nct_id>NCT02946879</nct_id>
  </id_info>
  <brief_title>Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)</brief_title>
  <official_title>Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno-associated Virus Vector (AAV2/5-OPTIRPE65) for Gene Therapy of Adults and Children With Retinal Dystrophy Owing to Defects in RPE65 (LCA2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MeiraGTx UK II Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syne Qua Non Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MeiraGTx UK II Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a longer-term follow-up study for patients who have been administered
      AAV2/5-OPTIRPE65 in the Phase I/II, open label, non-randomised, two-centre, dose escalation
      trial in adults and children with retinal dystrophy associated with defects in RPE65.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The follow up study is designed to collect data on longer-term safety and efficacy of
      AAV2/5-OPTIRPE65 administration in the OPTIRPE65 trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events related to the treatment</measure>
    <time_frame>5 years</time_frame>
    <description>Safety is defined as the absence of ATIMP-related safety events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in the retinal function</measure>
    <time_frame>5 years</time_frame>
    <description>Improvements in visual function as assessed by visual assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in the visual function</measure>
    <time_frame>5 years</time_frame>
    <description>Improvements in retinal function as assessed by visual assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life</measure>
    <time_frame>5 years</time_frame>
    <description>Improvement in the participant's quality of life which is measurable by QoL questionnaire</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Leber Congenital Amaurosis (LCA)</condition>
  <condition>Eye Diseases</condition>
  <condition>Eye Diseases, Hereditary</condition>
  <condition>Retinal Diseases</condition>
  <arm_group>
    <arm_group_label>Low dose AAV OPTIRPE65</arm_group_label>
    <description>subretinal administration of a single low dose of AAV RPE65</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate dose AAV OPTIRPE65</arm_group_label>
    <description>subretinal administration of a single intermediate dose of AAV RPE65</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose AAV OPTIRPE65</arm_group_label>
    <description>subretinal administration of a single highdose of AAV RPE65</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AAV OPTIRPE65</intervention_name>
    <description>comparison of different doses of AAV RPE65</description>
    <arm_group_label>Low dose AAV OPTIRPE65</arm_group_label>
    <arm_group_label>Intermediate dose AAV OPTIRPE65</arm_group_label>
    <arm_group_label>High dose AAV OPTIRPE65</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patient population are those with Leber Congenital Amaurosis (LCA) with gene mutation
        RPE65 who have participated in the OPTIRPE65 trial.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Were enrolled and treated in the prior open-label, Phase I/II, dose escalation study
             involving intraocular administration of AAV2/5-OPTIRPE65

        Exclusion Criteria:

          -  Individuals will be excluded if they are unwilling or unable to meet with the
             requirements of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julie Bakobaki, MSc</last_name>
    <phone>+44 (0)20 3866 4320</phone>
    <email>julie.bakobaki@meiragtx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Praseeda Thaikalloor, MSc</last_name>
    <email>praseeda.thaikalloor@meiragtx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moorfields Eye Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Michaelides</last_name>
      <email>michel.michaelides@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>James Bainbridge, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel Michaelides, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2016</study_first_posted>
  <last_update_submitted>December 15, 2017</last_update_submitted>
  <last_update_submitted_qc>December 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Blindness</mesh_term>
    <mesh_term>Leber Congenital Amaurosis</mesh_term>
    <mesh_term>Retinal Dystrophies</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Eye Diseases, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

